**MarketVIEW: Herpes Simplex Virus (TX) vaccines** *(CAT: VAMV038)*

**Product Name**: MarketVIEW: Herpes Simplex Virus therapeutic (TX) vaccines

**Description**: Global vaccine commercial opportunity assessment

**Contents**: Executive presentation + 1 forecast model

**Therapeutic Area**: Pediatric/adults vaccines

**Publication date**: July 2012

**Catalogue No**: VAMV038

**Background**

Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.

Vaccine manufacturers have pursued the development of both prophylactic (PX) and therapeutic (TX) HSV vaccines albeit with little success to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need for long-term pharmacotherapy. Ideally the vaccine would also reduce transmission so having a wider public health benefit.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a therapeutic across the major Western markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. **LO/BASE/HI** target product profile (TPP) scenarios are included which examine the uptake of vaccines with differing clinical performance. A detailed review is also included on latest trends in disease epidemiology/dynamics.

---

1 **VacZine Analytics** has also published on prophylactic HSV vaccines. Please see CAT No: VAMV016, published February 2011
Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to Herpes Simplex Virus (HSV-1/2) epidemiology/vaccines and consulted with global experts regarding their predictions of vaccine deployment. Secondary source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the adolescent field has also been utilised.

**PRODUCT CONTENTS:**

**Published July 2012 (CAT No: VAMV038)**

****This product is composed of a model and summary presentation****

**Contents – Summary presentation (MS PowerPoint based)**

- Author’s note
- Executive Summary
- Point(s) to note regarding vaccine pricing/usage
- Commercial model – key model outputs
- HSV TX vaccine: available market ($000s) to 2030 by scenario
- HSV TX vaccine: demand (000s doses) to 2030 by scenario
- HSV TX vaccine: available market ($000s) to 2030 (low scenario)
- HSV TX vaccine: available market ($000s) to 2030 (base scenario)
- HSV TX vaccine: available market ($000s) to 2030 (high scenario)
- HSV TX vaccine: available market ($000s) to 2030 by country (base scenario)
- HSV therapeutic vaccines: commercial model assumptions
- Current management of genital herpes
- The role of HSV TX vaccines
- HSV TX vaccine target populations (scenario definition)
- HSV TX vaccine: target product profile(s)
- Model assumptions: populations/penetration rates/pricing/launch sequence
- Markets included in model
- Commercial model assumptions per TPP (LO/BASE/HI)
- HSV TX vaccine segment analysis
- Contribution of HSV-1 and HSV-2 to commercial value
- HSV therapeutic vaccines: R&D pipeline
- Competitor landscape: overview
- HSV TX vaccine pipeline
- Agenus
- Preclinical programs
- HSV therapeutic vaccines: Review on latest epidemiology
- HSV-1/HSV-2: overview
- HSV surveillance
- Epidemiology: UK
- Epidemiology: US
- Epidemiology: other markets
- HSV-1 and HSV-2 seroprevalence studies
Continued………

Role of HSV-1 as a cause of genital herpes
Clinical reactivation of HSV-1 and HSV-2
Methodology: Calculating TX vaccine target populations
Bibliography
About VacZine Analytics
Disclaimer

PAGES: 66 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
Scenario definition
Chart – value
Chart – volume
Volume summary
Value summary (High price)
Value summary (Base price)
Value summary (Low price)
Country worksheets ➔
US
Canada
UK
France
Spain
Italy
Germany
Other EU
Japan
Australia
Sources
Herpes database (UK)
Herpes database (US)
Diagnoses rates
US NDTI diagnoses
UK HPA diagnoses
UK HPA by age
US HSV-2 seroprevalence
Back page

WORKSHEETS = 30
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $8995.00/ GBP £6000.00 (Region license)*

* A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included but not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

BIBLIOGRAPHY:
8. Agenus Inc Form 10k. For the fiscal year ended December 31, 2011

CONTINUED......

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009